David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes
DME Capital Management reveals its new third-quarter stock picks. Here's what David Einhorn has been buying.

Last updated: 2026-11-19 02:28:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Immunovant, Inc. (IMVT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $33.18, with a market capitalization of $6.89B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $21.86 to $45.42. This page covers its latest market performance, valuation, price trends and company information.
$6.89B | |
$33.07 | |
$34.92 | |
$31.03 | |
$33.21 | |
549.36K | |
1.43M | |
-- | |
$45.42 | |
$21.86 | |
-- | |
2026-09-30 |
Immunovant, Inc. (IMVT) last closed at $33.18 as of 2026-11-19 00:31:00, down 0.06% ($0.02) from the previous close of $33.21.
During the latest regular trading session, IMVT traded between $31.03 and $34.92, with a volume of 549.36K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Immunovant, Inc. (IMVT) moved from $35.15 to $33.18, representing a decline of 5.60% ($1.97).
The stock traded between $31.03 and $37.59 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.62 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 48.0%
IMVT is currently trading at $33.18, placing it 48.0% of the way from its 52-week low of $21.86 to its 52-week high of $45.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 315 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Immunovant, Inc. and IMVT stock.
DME Capital Management reveals its new third-quarter stock picks. Here's what David Einhorn has been buying.
Immunovant (IMVT) has gained 24.4% over the past four weeks and Wall Street analysts project a mean price target of $46.61, indicating a potential 30.5% upside from current levels of $35.71. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, though the article cautions that price targets alone should not be the sole basis for investment decisions.
Immunovant, Inc. (IMVT) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate has increased 1.1% over the past three months. The upgrade positions IMVT in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving earnings outlook.
Eligible investors can buy real shares of Immunovant, Inc. (IMVT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to IMVT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between IMVT shares and USD.
IMVT Shares to USD
1.00 IMVT shares = 33.18 USD
Calculations are estimates based on the latest available price and are for reference only.